Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic

Introduction: Tenecteplase (TNK) has demonstrated to be non-inferior to alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). There are potential workflow benefits associated with TNK use, aiming to reduce patient length of stay in the emergency department. Ou...

Full description

Saved in:
Bibliographic Details
Main Authors: Matias Guzman, Pablo M. Lavados, Gabriel Cavada, Alejandro M. Brunser, Veronica V. Olavarria
Format: Article
Language:English
Published: Karger Publishers 2025-02-01
Series:Cerebrovascular Diseases Extra
Online Access:https://karger.com/article/doi/10.1159/000543900
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850274820074242048
author Matias Guzman
Pablo M. Lavados
Gabriel Cavada
Alejandro M. Brunser
Veronica V. Olavarria
author_facet Matias Guzman
Pablo M. Lavados
Gabriel Cavada
Alejandro M. Brunser
Veronica V. Olavarria
author_sort Matias Guzman
collection DOAJ
description Introduction: Tenecteplase (TNK) has demonstrated to be non-inferior to alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). There are potential workflow benefits associated with TNK use, aiming to reduce patient length of stay in the emergency department. Our aim was to investigate whether the routine use of TNK during the COVID-19 pandemic influenced workflow times compared to historical use of ALT, while maintaining non-inferior clinical outcomes in a non-drip and ship scenario of a comprehensive stroke center. Methods: We included patients with AIS admitted from September 2019 to September 2022 and compared those treated with TNK during the COVID-19 pandemic to those treated with ALT in the period immediately before. We compared emergency department length of stay (EDLOS), door-to-needle time (DTN), door-to-groin puncture time (DTG), clinical and safety outcomes with adjusted general linear regression models. Results: 110 patients treated with TNK and 111 with ALT were included in this study. Mean EDLOS was 251 (SD = 164) min for TNK users versus 240 (SD = 148) min for ALT (p = 0.62). Mean DTN was 43 (SD = 25) min for TNK versus 46 (SD = 27) min for ALT users (p = 0.39). Mean DTN under 60 min was achieved in 86 (78.2%) patients and in 85 (76.5%) patients of the TNK and ALT groups, respectively (p = 1.0). DTN under 45 min was achieved in 65.4% and 58.6% (p = 0.65) of the TNK and ALT groups, respectively. DTG time was 114 (SD = 43) min for TNK versus 111 (58 = SD) min in the ALT group (p = 0.88). DTG under 90 min was achieved in 32% of the TNK group and 35% of the ALT group (p = 0.69). There were no differences in any of the clinical or safety outcomes between groups at 90 days. Conclusions: The adoption of TNK during COVID-19 pandemic did not result in a change in EDLOS, DTN, or DTG times when compared to ALT in this cohort. Safety and clinical outcomes were similar between groups. Probably a greater benefit could have been seen in a drip and ship thrombolysis setting. Further research is needed to assess the potential advantages of TNK in drip and ship scenarios of IVT.
format Article
id doaj-art-190d0eb455d849508737d8932ba58ea2
institution OA Journals
issn 1664-5456
language English
publishDate 2025-02-01
publisher Karger Publishers
record_format Article
series Cerebrovascular Diseases Extra
spelling doaj-art-190d0eb455d849508737d8932ba58ea22025-08-20T01:51:02ZengKarger PublishersCerebrovascular Diseases Extra1664-54562025-02-0115110210910.1159/000543900Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 PandemicMatias GuzmanPablo M. LavadosGabriel CavadaAlejandro M. Brunserhttps://orcid.org/0000-0002-8376-9450Veronica V. Olavarria Introduction: Tenecteplase (TNK) has demonstrated to be non-inferior to alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). There are potential workflow benefits associated with TNK use, aiming to reduce patient length of stay in the emergency department. Our aim was to investigate whether the routine use of TNK during the COVID-19 pandemic influenced workflow times compared to historical use of ALT, while maintaining non-inferior clinical outcomes in a non-drip and ship scenario of a comprehensive stroke center. Methods: We included patients with AIS admitted from September 2019 to September 2022 and compared those treated with TNK during the COVID-19 pandemic to those treated with ALT in the period immediately before. We compared emergency department length of stay (EDLOS), door-to-needle time (DTN), door-to-groin puncture time (DTG), clinical and safety outcomes with adjusted general linear regression models. Results: 110 patients treated with TNK and 111 with ALT were included in this study. Mean EDLOS was 251 (SD = 164) min for TNK users versus 240 (SD = 148) min for ALT (p = 0.62). Mean DTN was 43 (SD = 25) min for TNK versus 46 (SD = 27) min for ALT users (p = 0.39). Mean DTN under 60 min was achieved in 86 (78.2%) patients and in 85 (76.5%) patients of the TNK and ALT groups, respectively (p = 1.0). DTN under 45 min was achieved in 65.4% and 58.6% (p = 0.65) of the TNK and ALT groups, respectively. DTG time was 114 (SD = 43) min for TNK versus 111 (58 = SD) min in the ALT group (p = 0.88). DTG under 90 min was achieved in 32% of the TNK group and 35% of the ALT group (p = 0.69). There were no differences in any of the clinical or safety outcomes between groups at 90 days. Conclusions: The adoption of TNK during COVID-19 pandemic did not result in a change in EDLOS, DTN, or DTG times when compared to ALT in this cohort. Safety and clinical outcomes were similar between groups. Probably a greater benefit could have been seen in a drip and ship thrombolysis setting. Further research is needed to assess the potential advantages of TNK in drip and ship scenarios of IVT. https://karger.com/article/doi/10.1159/000543900
spellingShingle Matias Guzman
Pablo M. Lavados
Gabriel Cavada
Alejandro M. Brunser
Veronica V. Olavarria
Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
Cerebrovascular Diseases Extra
title Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
title_full Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
title_fullStr Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
title_full_unstemmed Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
title_short Emergency Department Workflow Times of Intravenous Thrombolysis with Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Prospective Cohort Study before and during the COVID-19 Pandemic
title_sort emergency department workflow times of intravenous thrombolysis with tenecteplase versus alteplase in acute ischemic stroke a prospective cohort study before and during the covid 19 pandemic
url https://karger.com/article/doi/10.1159/000543900
work_keys_str_mv AT matiasguzman emergencydepartmentworkflowtimesofintravenousthrombolysiswithtenecteplaseversusalteplaseinacuteischemicstrokeaprospectivecohortstudybeforeandduringthecovid19pandemic
AT pablomlavados emergencydepartmentworkflowtimesofintravenousthrombolysiswithtenecteplaseversusalteplaseinacuteischemicstrokeaprospectivecohortstudybeforeandduringthecovid19pandemic
AT gabrielcavada emergencydepartmentworkflowtimesofintravenousthrombolysiswithtenecteplaseversusalteplaseinacuteischemicstrokeaprospectivecohortstudybeforeandduringthecovid19pandemic
AT alejandrombrunser emergencydepartmentworkflowtimesofintravenousthrombolysiswithtenecteplaseversusalteplaseinacuteischemicstrokeaprospectivecohortstudybeforeandduringthecovid19pandemic
AT veronicavolavarria emergencydepartmentworkflowtimesofintravenousthrombolysiswithtenecteplaseversusalteplaseinacuteischemicstrokeaprospectivecohortstudybeforeandduringthecovid19pandemic